A smooth blood pressure control is obtained over 24 h by delapril in mild to moderate essential hypertensives

Blood Pressure

Volumn 10, Issue 3, 2001, Pages 170-175

  Omboni, S ^a   Fogari, R ^a   Mancia, G ^a  

^a NONE   (Italy)

Author keywords

Ambulatory blood pressure monitoring; Delapril; Essential hypertension; Pulse pressure; Smoothness index; Trough to peak ratio

Indexed keywords

ANTIHYPERTENSIVE AGENT; DELAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CALCULATION; CLINICAL TRIAL; COUGHING; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; ESSENTIAL HYPERTENSION; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PARAMETER; PRIORITY JOURNAL; PROGNOSIS; PULSE PRESSURE; SPHYGMOMANOMETRY; STOMACH DISEASE; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CIRCADIAN RHYTHM; FEMALE; HUMANS; HYPERTENSION; INDANS; MALE; MIDDLE AGED;

EID: 0034765754     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/080370501753182398     Document Type: Article

References (34)

1. Characteristics of a new angiotensin converting enzyme inhibitor: Delapril
2. Clinical evaluation of delapril in Japan. Report from the Japan Study Group on Delapril
3. A 12-month comparison of ACE inhibitor and Ca antagonist therapy in mild to moderate essential hypertension. The GLANT study
4. Practitioner's Trial on the Efficacy of Antihypertensive Treatment in the Elderly Hypertension (The PATE-Hypertension Study) in Japan
5. Effects of longterm treatment with delapril on quality of life in hypertensive patients
6. Effects of manidipine and delapril on serum lipids, lipoproteins, and apolipoproteins in patients with mild to moderate essential hypertension: A randomized trial with one-year follow-up
7. Clinical evaluation of delapril hydrochloride (Adecut) on circadian variation of blood pressure with essential hypertension. Effect of initial dose and comparison between twice and once a day regimen
8. A study of the effects of delapril, a new angiotensin converting enzyme inhibitor, on the diurnal variation of arterial pressure in patients with essential hypertension using indirect and direct arterial pressure monitoring methods
9. Effects of delapril hydrochloride on essential hypertension assessed by 24-hour blood pressure monitoring
10. Efficacy of delapril in the treatment of mild to moderate essential hypertension: Evaluation by 24-hour ambulatory blood pressure monitoring
11. Relationship of 24-hour blood pressure mean and variability to severity of target organ damage in hypertension
12. Clinical relevance of nighttime blood pressure and daytime blood pressure variability
13. Prognostic value of 24-hour blood pressure variability
14. Calculation of trough: Peak ratio of antihypertensive treatment from ambulatory blood pressure: Methodological aspects
15. The smoothness index: A new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension
16. The trough: Peak ratio and the smoothness index in the evaluation of control of 24 h blood pressure by treatment in hypertension
17. Guidelines for 24 h non-invasive ambulatory blood pressure monitoring. Report from a working group of the Italian Society of Hypertension
18. Trough: Peak ratio: The rationale behind the United States Food and Drug Administration recommendations
19. Ambulatory 24-h blood pressure assessment of the felodipine-metoprolol combination versus amlodipine in mild to moderate hypertension
20. Double-blind, randomized, multicentre comparison of the effects of amlodipine and perindopril on 24 h therapeutic coverage and beyond in patients with mild to moderate hypertension
21. Lack of placebo effect on ambulatory blood pressure
22. Placebo does not lower ambulatory blood pressure
23. Does placebo lower blood pressure?
24. Risk factors associated with alterations in carotid intima-media thickness in hypertension: Baseline data from the European Lacidipine Study on Atherosclerosis
25. Pulse pressure and cardiovascular mortality in normotensive and hypertensive subjects
26. Pulse pressure as a risk factor for cardiovascular events in the MRC Mild Hypertension Trial
27. Converting anzyme inhibition modulates sympathetic neurotransmission in vivo via multiple mechanisms
28. Improvement of vagal tone by ACE inhibition: A mechanism of cardioprotection in patients with mild-to-moderate heart failure
29. Evaluation of the antihypertensive effect of once-a-day trandolapril by 24-hour ambulatory blood pressure monitoring
30. Heart rate and cardiovascular mortality: The Framingham Study
31. Heart rate and the cardiovascular risk
32. Ambulatory monitoring uncorrected for placebo overestimates longterm antihypertensive action